SuperworthQuanterix profit margin QTRX
Gross, operating and net profit as a share of revenue over the last twelve months, from 2018.
- Net margin, 12 months
- −80.2%
- Operating margin, 12 months
- −99.6%
- Net margin on a year earlier
- −24.2 pts
- Peer median
- 10.6%
Over the twelve months to Jun 30, 2026, Quanterix kept −80.2% of its revenue as net profit, with an operating margin of −99.6% and a gross margin of 42.7%.
Five years earlier its net margin was −26.9%.
The median for 10 healthcare stocks of a similar size is 10.6%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −77.1% | −90.4% | 44.7% |
| FY2024 | −28.0% | −38.3% | 60.5% |
| FY2023 | −23.2% | −37.6% | 60.7% |
| FY2022 | −94.4% | −98.8% | 43.0% |
| FY2021 | −52.2% | −53.0% | 55.8% |
| FY2020 | −36.5% | −36.6% | 55.8% |
| FY2019 | −71.9% | −73.3% | 47.3% |
| FY2018 | −83.8% | −83.8% | 47.7% |
| FY2017 | n/a | n/a | 43.7% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −80.2% | −24.2 pts | −99.6% | |
| Q1 FY26 | −71.9% | −36.6 pts | −96.9% | |
| Q4 FY25 | −77.1% | −49.1 pts | −90.4% | |
| Q3 FY25 | −73.5% | −46.8 pts | −88.8% | |
| Q2 FY25 | −56.0% | −29.7 pts | −71.5% | |
| Q1 FY25 | −35.3% | −9.7 pts | −47.0% | |
| Q4 FY24 | −28.0% | −4.9 pts | −38.3% | |
| Q3 FY24 | −26.7% | +5.7 pts | −38.5% | |
| Q2 FY24 | −26.3% | +34.2 pts | −40.5% | |
| Q1 FY24 | −25.6% | +59.6 pts | −40.1% | |
| Q4 FY23 | −23.2% | +71.2 pts | −37.6% | |
| Q3 FY23 | −32.4% | +59.8 pts | −46.1% |
Against its peers
Companies in Healthcare nearest Quanterix's size, closest first, today.
| Company | Profit margin |
|---|---|
| QTRXQuanterix | −80.2% |
| KEQUKewaunee Scientific | 3.0% |
| ICCCImmucell | 2.6% |
| PDEXPro DEX | 17.6% |
| PLXProtalix BioTherapeutics | 23.5% |
| NATRNatures Sunshine Products | 3.7% |
| ELMDElectromed | 15.3% |
| UTMDUtah Medical Products | 29.0% |
| LFVNLifevantage | 2.8% |
| INFUInfuSystem | 6.0% |
| SPROSpero Therapeutics | 15.7% |
| Peer median | 10.6% |
Where Quanterix ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Quanterix
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.